Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1434450
This article is part of the Research Topic Unveiling Biomarkers and Mechanisms in the Tumor-Immune Nexus View all 13 articles

Elucidating the Role of Tumor-Associated ALOX5+ Mast Cells with Transformative Function in Cervical Cancer Progression via Single-Cell RNA Sequencing

Provisionally accepted
  • 1 Shandong University of Traditional Chinese Medicine, Jinan, China
  • 2 Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, Jiangsu Province, China
  • 3 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
  • 4 Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, China
  • 5 Zhejiang Cancer Hospital, Hangzhou, China

The final, formatted version of the article will be published soon.

    Background Cervical cancer (CC) is the fourth most common malignancy among women globally and serves as the main cause of cancer-related deaths among women in developing countries. The early symptoms of CC are often not apparent, with diagnoses typically made at advanced stages, which lead to poor clinical prognoses. In recent years, numerous studies have shown that there is a close relationship between Mast cells (MCs) and tumor development. Method The present study acquired single-cell RNA sequencing data from ten CC tumor samples in the ArrayExpress database. Slingshot and AUCcell were utilized to infer and assess the differentiation trajectory and cell plasticity of MCs subpopulations. Differential expression analysis of MCs subpopulations in CC was performed, employing Gene Ontology, gene set enrichment analysis, and gene set variation analysis. Result The obtained 93,524 high-quality cells were classified into ten cell types, including T_NK cells, endothelial cells, fibroblasts, smooth muscle cells, epithelial cells, B cells, plasma cells, MCs, neutrophils, and myeloid cells. Furthermore, a total of 1,392 MCs were subdivided into seven subpopulations: C0 CTSG+ MCs, C1 CALR+ MCs, C2 ALOX5+ MCs, C3 ANXA2+ MCs, C4 MGP+ MCs, C5 IL32+ MCs, and C6 ADGRL4+ MCs. Notably, the C2 subpopulation showed close associations with tumor-related MCs, with Slingshot results indicating that C2 subpopulation resided at the intermediate-to-late stage of differentiation, potentially representing a crucial transition point in the benign-to-malignant transformation of CC. CNVscore and bulk analysis results further confirmed the transforming state of the C2 subpopulation. CellChat analysis revealed TNFRSF12A as a key receptor involved in the actions of C2 ALOX5+ MCs. Moreover, in vitro experiments confirmed that TNFRSF12A promotes the proliferation, migration, and invasion of CC cells. Additionally, a prognosis model and immune infiltration analysis based on the marker genes of the C2 subpopulation provided valuable guidance for patient prognosis and clinical intervention strategies. Conclusions We first identified the transformative tumor-associated MCs subgroup C2 ALOX5+ MCs within CC, which was at a critical stage of tumor differentiation and impacted the progression of CC.

    Keywords: Single-cell RNA-sequencing, cervical cancer, tumor heterogeneity, prognosis, cancer immunotherapy

    Received: 17 May 2024; Accepted: 24 Jul 2024.

    Copyright: © 2024 Zhao, Hong, Zhou, Huang, Lin, Zhang, Liang and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Guangyao Zhou, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300070, Tianjin, China
    Yining Zhang, Zhejiang Cancer Hospital, Hangzhou, China
    Lei L. Liang, Zhejiang Cancer Hospital, Hangzhou, China
    Huarong Tang, Zhejiang Cancer Hospital, Hangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.